Richard Schulz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4811092/publications.pdf

Version: 2024-02-01

198 papers	13,639 citations	26630 56 h-index	21540 114 g-index
199 all docs	199 docs citations	199 times ranked	10821 citing authors

#	Article	IF	Citations
1	Staurosporine-induced cleavage of apoptosis-inducing factor in human fibrosarcoma cells is independent of matrix metalloproteinase-2. Canadian Journal of Physiology and Pharmacology, 2022, 100, 184-191.	1.4	0
2	RPIâ€194 is a Novel Troponin Activator that Increases the Calcium Sensitivity of Striated Muscle Contraction. FASEB Journal, 2022, 36, .	0.5	0
3	Loss of Mitochondrial Dynamics Proteins Mitofusinâ€2 and Drpâ€1 in Myocardial Ischemiaâ€Reperfusion Injury Is Prevented by Matrix Metalloproteinaseâ€2 Preferring Inhibitors. FASEB Journal, 2022, 36, .	0.5	0
4	Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	0
5	MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling. Cardiovascular Research, 2021, 117, 188-200.	3.8	61
6	Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS Journal, 2021, 288, 7162-7182.	4.7	146
7	Matrix metalloproteinaseâ€2 mediates ribosomal RNA transcription by cleaving nucleolar histones. FEBS Journal, 2021, 288, 6736-6751.	4.7	13
8	Letter by Hwang et al Regarding Article, â€œTemporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humansâ€. Circulation, 2021, 144, e166-e167.	1.6	2
9	MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin. Biochemical Pharmacology, 2021, 193, 114744.	4.4	11
10	Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injuryâ€”Cardioprotective Properties of Carvedilol. Pharmaceuticals, 2021, 14, 1276.	3.8	7
11	Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemiaâ€“reperfusion injury. Cardiovascular Research, 2020, 116, 1021-1031.	3.8	16
12	Predictive Value of Matrix Metalloproteinases and Their Inhibitors for Mortality in Septic Patients: A Cohort Study. Journal of Intensive Care Medicine, 2020, 35, 95-103.	2.8	11
13	Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemiaâ€“reperfusion injury. Basic Research in Cardiology, 2019, 114, 42.	5.9	22
14	Prognostic Value of MMP-9 -1562 C/T Gene Polymorphism in Patients With Sepsis. Biomarker Insights, 2019, 14, 117727191984795.	2.5	5
15	Structure and proteolytic susceptibility of the inhibitory C-terminal tail of cardiac troponin I. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 661-671.	2.4	12
16	Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension. Vascular Pharmacology, 2019, 116, 36-44.	2.1	29
17	Proteolytic Digestion of Serum Cardiac Troponin I as Marker of Ischemic Severity. journal of applied laboratory medicine, The, 2018, 3, 450-455.	1.3	14
18	Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1238-1245.	1.4	12

#	Article	IF	Citations
19	High fat diet modulates inflammatory parameters in the heart and liver during acute Trypanosoma cruzi infection. International Immunopharmacology, 2018, 64, 192-200.	3.8	9
20	Matrix Metalloproteinase-2. , 2018, , 2996-3005.		0
21	Nucleolar Matrix Metalloproteinaseâ€2 Regulates rRNA Transcription. FASEB Journal, 2018, 32, lb416.	0.5	0
22	Matrix Metalloproteinase Inhibitors Attenuate Doxorubicinâ€Induced Heart Failure by Preventing Cardiac Titin Proteolysis. FASEB Journal, 2018, 32, 864.10.	0.5	0
23	TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: Multivariate model. PLoS ONE, 2017, 12, e0171191.	2.5	26
24	Doxycycline and Benznidazole Reduce the Profile of Th1, Th2, and Th17 Chemokines and Chemokine Receptors in Cardiac Tissue from ChronicTrypanosoma cruzi-Infected Dogs. Mediators of Inflammation, 2016, 2016, 1-11.	3.0	14
25	Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H183-H189.	3.2	16
26	Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. Journal of Molecular and Cellular Cardiology, 2016, 94, 153-161.	1.9	30
27	Matrix Metalloproteinase-2. , 2016, , 1-10.		1
28	Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial. Critical Care, 2015, 19, 226.	5.8	35
29	Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX, 2015, 2, 440-445.	1.6	145
30	Doxycycline Attenuates Renal Injury In A Swine Model Of Neonatal Hypoxia-Reoxygenation. Shock, 2015, 43, 99-105.	2.1	15
31	Morus nigra leaf extract improves glycemic response and redox profile in the liver of diabetic rats. Food and Function, 2015, 6, 3490-3499.	4.6	36
32	Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. International Journal of Cardiology, 2015, 197, 147-153.	1.7	23
33	Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. European Journal of Pharmacology, 2015, 765, 164-170.	3.5	12
34	ISDN2014_0147: The use of broccoli sprouts as a neuropreventative agent in a neonatal rat model of the fetal inflammatory response. International Journal of Developmental Neuroscience, 2015, 47, 43-43.	1.6	0
35	Dynamic Alterations to Î±-Actinin Accompanying Sarcomere Disassembly and Reassembly during Cardiomyocyte Mitosis. PLoS ONE, 2015, 10, e0129176.	2.5	21
36	Nuclear Localization and Biological Function of Matrix Metalloproteinaseâ€2. FASEB Journal, 2015, 29, 979.6.	0.5	0

#	Article	IF	Citations
37	The Activation of Matrix Metalloproteineaseâ€2 by Mitochondriallyâ€Generated Reactive Oxygen/Nitrogen Species. FASEB Journal, 2015, 29, 955.2.	0.5	0
38	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders, 2014, 14, 91.	1.7	27
39	MMP-2 is localized to the mitochondria-associated membrane of the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H764-H770.	3.2	40
40	Smoothelin-B is not a target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. Canadian Journal of Physiology and Pharmacology, 2014, 92, 887-891.	1.4	1
41	Myocardial matrix metalloproteinase-2: inside out and upside down. Journal of Molecular and Cellular Cardiology, 2014, 77, 64-72.	1.9	89
42	Targeting MMP-2 to treat ischemic heart injury. Basic Research in Cardiology, 2014, 109, 424.	5.9	69
43	Matrix metalloproteinases 2 and 9 as diagnostic tools in Chagas cardiomyopathy. International Journal of Cardiology, 2014, 177, 46-47.	1.7	4
44	Mmp25Î² facilitates elongation of sensory neurons during zebrafish development. Genesis, 2014, 52, 833-848.	1.6	11
45	Postresuscitation Administration of Doxycycline Preserves Cardiac Contractile Function in Hypoxia-Reoxygenation Injury of Newborn Piglets*. Critical Care Medicine, 2014, 42, e260-e269.	0.9	7
46	Remodeling of Aorta Extracellular Matrix as a Result of Transient High Oxygen Exposure in Newborn Rats: Implication for Arterial Rigidity and Hypertension Risk. PLoS ONE, 2014, 9, e92287.	2.5	25
47	Implications of Intracellular Proteolytic Activation of MMP-2 in the Heart. , 2014, , 335-349.		0
48	Matrix metalloproteinaseâ€2 is localized to the mitochondriaâ€associated membrane in the heart (1154.4). FASEB Journal, 2014, 28, 1154.4.	0.5	0
49	Matrix metalloproteinaseâ€2 mediate oncostatinâ€M induced cardiomyocyte dedifferentiation (1151.2). FASEB Journal, 2014, 28, 1151.2.	0.5	0
50	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. Biochemical Pharmacology, 2013, 86, 469-475.	4.4	12
51	Hydrogen peroxide-induced necrotic cell death in cardiomyocytes is independent of matrix metalloproteinase-2. Toxicology in Vitro, 2013, 27, 1686-1692.	2.4	26
52	Activation of intracellular matrix metalloproteinase-2 by reactive oxygenâ€“nitrogen species: Consequences and therapeutic strategies in the heart. Archives of Biochemistry and Biophysics, 2013, 540, 82-93.	3.0	45
53	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. American Heart Journal, 2013, 165, 558-566.	2.7	44
54	Doxycycline Reduces Cardiac Matrix Metalloproteinase-2 Activity but Does not Ameliorate Myocardial Dysfunction During Reperfusion in Coronary Artery Bypass Patients Undergoing Cardiopulmonary Bypass. Critical Care Medicine, 2013, 41, 2512-2520.	0.9	25

#	Article	IF	Citations
55	Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism. Journal of Cellular and Molecular Medicine, 2013, 17, 1588-1597.	3.6	13
56	Phosphorylation Status of 72 kDa MMP-2 Determines Its Structure and Activity in Response to Peroxynitrite. PLoS ONE, 2013, 8, e71794.	2.5	35
57	Intracellular Matrix Remodeling and Cardiac Function in Ischemiaâ€“Reperfusion Injury. , 2013, , 467-485.		0
58	Doxycycline Attenuates Cardiac Injury and Improves Cardiac Function with Inhibition of Myocardial Matrix Metalloproteinase (MMP)â€2 in a Swine Model of Hypoxiaâ€•Reoxygenation (Hâ€R). FASEB Journal, 2013, 27, 1129.9.	0.5	0
59	Role of MMPâ€2 activation in oncostatinâ€M induced cardiomyocyte dedifferentiation. FASEB Journal, 2013, 27, 1146.4.	0.5	0
60	Analysis of mitochondrial MMPâ€2 and MMPâ€9 in the heart. FASEB Journal, 2013, 27, 1129.10.	0.5	0
61	Intracellular proteases and sarcomere disassembly in neonatal cardiomyocytes. FASEB Journal, 2013, 27, 1217.33.	0.5	0
62	Nuclear MMPâ€2: presence and activity in cardiac myocytes. FASEB Journal, 2013, 27, 995.4.	0.5	0
63	Matrix Metalloproteinase-2 Proteolysis of Calponin-1 Contributes to Vascular Hypocontractility in Endotoxemic Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 662-668.	2.4	40
64	Matrix metalloproteinase-2: an emerging biomarker for reperfusion injury following percutaneous coronary intervention. Heart, 2012, 98, 1-2.	2.9	8
65	Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemiaâ€“reperfusion injury. Heart, 2012, 98, 656-662.	2.9	17
66	Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochemical and Biophysical Research Communications, 2012, 423, 1-5.	2.1	38
67	Mechanisms of cytosolic targeting of matrix metalloproteinaseâ€2. Journal of Cellular Physiology, 2012, 227, 3397-3404.	4.1	68
68	Ischemia/reperfusionâ€•induced myosin light chainâ€ƒ1 phosphorylation increases its degradation by matrix metalloproteinaseâ€ƒ2. FEBS Journal, 2012, 279, 2444-2454.	4.7	36
69	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)â€2. FASEB Journal, 2012, 26, lb657.	0.5	0
70	Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. Pharmacological Research, 2011, 64, 551-560.	7.1	80
71	Intracellular MMP-2: Role in Normal and Diseased Hearts. , 2011, , 17-28.		0
72	Cardiac Sarcomeric Proteins: Novel Intracellular Targets of Matrix Metalloproteinase-2 in Heart Disease. Trends in Cardiovascular Medicine, 2011, 21, 112-118.	4.9	54

#	Article	IF	Citations
73	Smoothelinâ€B: a potential target of matrix metalloproteinase (MMP)â€2 in the vasculature of endotoxemic rats. FASEB Journal, 2011, 25, 1115.19.	0.5	0
74	Peroxynitriteâ€induced changes in 72kDa matrix metalloproteinaseâ€2 activity are further regulated by its phosphorylation status. FASEB Journal, 2011, 25, 1096.2.	0.5	0
75	Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress. Journal of Nutritional Biochemistry, 2010, 21, 827-833.	4.2	40
76	Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovascular Research, 2010, 85, 413-423.	3.8	229
77	Cardiac function is not significantly diminished in hearts isolated from young caveolin-1 knockout mice. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1183-H1189.	3.2	12
78	Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H45-H51.	3.2	58
79	Titin is a Target of Matrix Metalloproteinase-2. Circulation, 2010, 122, 2039-2047.	1.6	177
80	Caveolin-1 exists and may function in cardiomyocytes. Canadian Journal of Physiology and Pharmacology, 2010, 88, 73-76.	1.4	19
81	Activation of MMP-2 as a key event in oxidative stress injury to the heart. Frontiers in Bioscience - Landmark, 2009, Volume, 699.	3.0	22
82	Plasma Matrix Metalloproteinases in Neonates Having Surgery for Congenital Heart Disease. Heart International, 2009, 4, hi.2009.e4.	1.4	1
83	Matrix Metalloproteinase-7 and ADAM-12 (a Disintegrin and Metalloproteinase-12) Define a Signaling Axis in Agonist-Induced Hypertension and Cardiac Hypertrophy. Circulation, 2009, 119, 2480-2489.	1.6	73
84	Glycogen synthase kinase-3Â is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovascular Research, 2009, 83, 698-706.	3.8	40
85	Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochemical Pharmacology, 2009, 77, 826-834.	4.4	190
86	Post-resuscitation NOS inhibition does not improve hemodynamic recovery of hypoxic newborn pigs. Intensive Care Medicine, 2009, 35, 1628-1635.	8.2	1
87	Proteomics analysis of changes in myocardial proteins during endotoxemia. Journal of Proteomics, 2009, 72, 648-655.	2.4	10
88	Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochemical and Biophysical Research Communications, 2009, 387, 646-650.	2.1	40
89	Cleavage of glycogen synthase kinaseâ€3beta by matrix metalloproteinaseâ€2 enhances its kinase activity. FASEB Journal, 2009, 23, 577.6.	0.5	0
90	Does caveolinâ€1 knockout affect matrix metalloproteinaseâ€2 activity and contractile function in the isolated working mouse heart?. FASEB Journal, 2009, 23, 812.3.	0.5	0

#	Article	IF	Citations
91	Effect of Multiparity on Vascular Compliance and Collagen Content. FASEB Journal, 2009, 23, 951.7.	0.5	0
92	Matrix metalloproteinaseâ€2 coâ€localizes with titin in cardiac myocytes and contributes to its proteolysis in ischemiaâ€reperfusion injury. FASEB Journal, 2009, 23, 812.11.	0.5	0
93	Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Research in Cardiology, 2008, 103, 431-443.	5.9	48
94	Protective action of doxycycline against diabetic cardiomyopathy in rats. British Journal of Pharmacology, 2008, 155, 1174-1184.	5.4	63
95	Inhibition of matrix metalloproteinases prevents peroxynitriteâ€induced contractile dysfunction in the isolated cardiac myocyte. British Journal of Pharmacology, 2008, 153, 676-683.	5.4	33
96	Peroxynitrite inactivates humanâ€tissue inhibitor of metalloproteinaseâ€4. FEBS Letters, 2008, 582, 1135-1140.	2.8	49
97	Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide. European Journal of Pharmacology, 2008, 582, 116-122.	3.5	13
98	Calcium extrusion by plasma membrane calcium pump is impaired in caveolin-1 knockout mouse small intestine. European Journal of Pharmacology, 2008, 591, 80-87.	3.5	29
99	Smooth muscle NOS, colocalized with caveolinâ€1, modulates contraction in mouse small intestine. Journal of Cellular and Molecular Medicine, 2008, 12, 1404-1415.	3.6	20
100	Increased Activities of Cardiac Matrix Metalloproteinases Matrix Metalloproteinase (MMP)â€“2 and MMPâ€9 Are Associated with Mortality during the Acute Phase of ExperimentalTrypanosoma cruziInfection. Journal of Infectious Diseases, 2008, 197, 1468-1476.	4.0	90
101	Role of oxidative stress in multiparity-induced endothelial dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1736-H1742.	3.2	28
102	Calcium extrusion by plasma membrane calcium pump is impaired in absence of intact caveolae. FASEB Journal, 2008, 22, 916.8.	0.5	1
103			

#	Article	IF	Citations
109	Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. Journal of Molecular and Cellular Cardiology, 2007, 42, 896-901.	1.9	68
110	Matrix metalloproteinase-2 degrades the cytoskeletal protein Î±-actinin in peroxynitrite mediated myocardial injury. Journal of Molecular and Cellular Cardiology, 2007, 43, 429-436.	1.9	147
111	Differential inhibitory control of circular and longitudinal smooth muscle layers of Balb/C mouse small intestine. Autonomic Neuroscience: Basic and Clinical, 2007, 131, 36-44.	2.8	10
112	Intracellular Targets of Matrix Metalloproteinase-2 in Cardiac Disease: Rationale and Therapeutic Approaches. Annual Review of Pharmacology and Toxicology, 2007, 47, 211-242.	9.4	263
113	Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. British Journal of Pharmacology, 2007, 152, 189-205.	5.4	174
114	Matrix metalloproteinaseâ€2, caveolins, focal adhesion kinase and câ€Kit in cells of the mouse myocardium. Journal of Cellular and Molecular Medicine, 2007, 11, 1069-1086.	3.6	34
115	Isolated heart perfusion according to Langendorffâ€”Still viable in the new millennium. Journal of Pharmacological and Toxicological Methods, 2007, 55, 113-126.	0.7	270
116	Smooth muscle nitric oxide synthase, coâ€localized with caveolinâ€1, modulates contraction in mouse small intestine. FASEB Journal, 2007, 21, A808.	0.5	0
117	Detection of specific nitrotyrosine-modified proteins as a marker of oxidative stress in cardiovascular disease. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H2167-H2168.	3.2	37
118	Matrix metalloproteinases contribute to endotoxin and interleukinâ€1 Î² induced vascular dysfunction. British Journal of Pharmacology, 2006, 149, 31-42.	5.4	44
119	The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver. Current Pharmaceutical Design, 2006, 12, 2923-2934.	1.9	42
120	Impact of caveolin-1 knockout on NANC relaxation in circular muscles of the mouse small intestine compared with longitudinal muscles. American Journal of Physiology - Renal Physiology, 2006, 290, G394-G403.	3.4	12
121	Caveolin-1 knockout alters Î²-adrenoceptors function in mouse small intestine. American Journal of Physiology - Renal Physiology, 2006, 291, G1020-G1030.	3.4	12
122	Hyperlipidemia Attenuates the Infarct Size-Limiting Effect of Ischemic Preconditioning: Role of Matrix Metalloproteinase-2 Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 154-161.	2.5	109
123	Caveolinâ€1 knockout alters Î²â€adrenoceptor (Î²â€AR) function in mouse small intestine. FASEB Journal, 2006, 20, .	0.5	0
124	Inhibition of endogenous nitric oxide in the heart enhances matrix metalloproteinase-2 release. British Journal of Pharmacology, 2005, 145, 43-49.	5.4	24
125	Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury. Circulation, 2005, 112, 544-552.	1.6	269
126	Ischaemiaâ€“reperfusion injury activates matrix metalloproteinases in the human heart. European Heart Journal, 2005, 26, 27-35.	2.2	122

#	Article	IF	Citations
127	The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. Journal of Molecular and Cellular Cardiology, 2005, 39, 833-840.	1.9	55
128	Nitrosative stress and pharmacological modulation of heart failure. Trends in Pharmacological Sciences, 2005, 26, 302-310.	8.7	217
129	Turmoil in the Cardiac Myocyte: Acute Intracellular Activation of Matrix Metalloproteinases. , 2005, , 213-237.		0
130	MMP-2 and MMP-9 and Their Tissue Inhibitors in the Plasma of Preterm and Term Neonates. Pediatric Research, 2004, 55, 794-801.	2.3	62
131	Pyruvate prevents cardiac dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. Canadian Journal of Physiology and Pharmacology, 2004, 82, 409-416.	1.4	25
132	Physiological levels of amyloid peptides stimulate the angiogenic response through FGFâ€2. FASEB Journal, 2004, 18, 1943-1945.	0.5	48
133	Matrix metalloproteinaseâ€2 (MMPâ€2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADPâ€ribose) polymerase (PARP) in vitro. FASEB Journal, 2004, 18, 690-692.	0.5	225
134	Inhibition of inducible nitric oxide synthase and superoxide production reduces matrix metalloproteinase-9 activity and restores coronary vasomotor function in rat cardiac allografts. European Journal of Cardio-thoracic Surgery, 2004, 26, 262-269.	1.4	25
135	Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Critical Care Medicine, 2004, 32, 1332-1337.	0.9	34
136	Peroxynitrite in Myocardial Ischemia-Reperfusion Injury. , 2004, , 201-211.		14
137	Title is missing!. Molecular and Cellular Biochemistry, 2003, 251, 61-66.	3.1	40
138	Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. British Journal of Pharmacology, 2003, 138, 532-543.	5.4	378
139	Inhaled nitric oxide inhibits the release of matrix metalloproteinase-2, but not platelet activation, during extracorporeal membrane oxygenation in adult rabbits. Journal of Pediatric Surgery, 2003, 38, 534-538.	1.6	6
140	Imbalance Between Tissue Inhibitor of Metalloproteinase-4 and Matrix Metalloproteinases During Acute Myoctardial Ischemia-Reperfusion Injury. Circulation, 2003, 107, 2487-2492.	1.6	109
141	Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovascular Research, 2003, 57, 426-433.	3.8	119
142	Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. , 2003, , 61-66.		16
143	Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Molecular and Cellular Biochemistry, 2003, 251, 61-6.	3.1	15
144	Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury. Circulation, 2002, 106, 1543-1549.	1.6	434

#	Article	IF	Citations
145	Poly(ADP-Ribose) Polymerase Inhibition Reduces Reperfusion Injury After Heart Transplantation. Circulation Research, 2002, 90, 100-106.	4.5	160
146	Nitrate tolerance does not increase production of peroxynitrite in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H69-H76.	3.2	25
147	Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1108-H1115.	3.2	127
148	Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochemical and Biophysical Research Communications, 2002, 296, 937-941.	2.1	58
149	Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovascular Research, 2002, 53, 165-174.	3.8	167
150	Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Failure Reviews, 2002, 7, 359-369.	3.9	34
151	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. Journal of Clinical Investigation, 2002, 109, 735-743.	8.2	220
152	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. Journal of Clinical Investigation, 2002, 109, 735-743.	8.2	132
153	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. Journal of Clinical Investigation, 2002, 109, 735-743.	8.2	38
154	Peroxynitrite: Toxic or Protective in the Heart?. Circulation Research, 2001, 88, E12-3.	4.5	26
155	Inhibition of Peroxynitrite-Induced Dityrosine Formation with Oxidized and Reduced Thiols, Nitric Oxide Donors, and Purine Derivatives. Antioxidants and Redox Signaling, 2001, 3, 165-171.	5.4	11
156	Roles of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury and ischemic preconditioning. , 2001, , 191-206.		3
157	The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Critical Care Medicine, 2000, 28, 2584-2590.	0.9	138
158	Influence of Î²-adrenoceptor tone on the cardioprotective efficacy of adenosine A1 receptor activation in isolated working rat hearts. British Journal of Pharmacology, 2000, 131, 537-545.	5.4	1
159	Peroxynitrite Is a Major Contributor to Cytokine-Induced Myocardial Contractile Failure. Circulation Research, 2000, 87, 241-247.	4.5	425
160	The hemodynamic effects of inhaled nitric oxide and endogenous nitric oxide synthesis blockade in newborn piglets during infusion of heat-killed group B streptococci. Critical Care Medicine, 2000, 28, 800-808.	0.9	24
161	Upregulation of neuronal nitric oxide synthase in skeletal muscle by swim training. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1757-H1766.	3.2	42
162	Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion Injury in the Heart. Circulation, 2000, 101, 1833-1839.	1.6	415

#	Article	IF	Citations
163	Glutathione Protects Against Myocardial Ischemiaâ€“reperfusion Injury by Detoxifying Peroxynitrite. Journal of Molecular and Cellular Cardiology, 2000, 32, 1669-1678.	1.9	60
164	Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R265-R276.	1.8	118
165	Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1861-H1867.	3.2	43
166	Classic Preconditioning Decreases the Harmful Accumulation of Nitric Oxide During Ischemia and Reperfusion in Rat Hearts. Circulation, 1999, 100, 2260-2266.	1.6	121
167	Response of Fetal Rabbit Ductus Arteriosus to Bradykinin: Role of Nitric Oxide, Prostaglandins, and Bradykinin Receptors. Pediatric Research, 1999, 45, 568-574.	2.3	15
168	KATP -channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1 -receptor stimulation. British Journal of Pharmacology, 1998, 124, 639-646.	5.4	11
169	Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet, The, 1998, 351, 1181-1182.	13.7	73
170	Thiols Protect the Inhibition of Myocardial Aconitase by Peroxynitrite. Archives of Biochemistry and Biophysics, 1998, 350, 104-108.	3.0	54
171	Intrinsic ANG II type 1 receptor stimulation contributes to recovery of postischemic mechanical function. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1524-H1531.	3.2	6
172	Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1971-H1978.	3.2	18
173	Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1016-H1023.	3.2	38
174	Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovascular Research, 1997, 33, 422-432.	3.8	308
175	Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 272, H1212-H1219.	3.2	65
176	Nitric oxide and platelet function: Implications for neonatology. Seminars in Perinatology, 1997, 21, 409-417.	2.5	77
177	Rapid increase in inducible nitric oxide synthase gene expression in the heart during endotoxemia. European Journal of Pharmacology, 1996, 303, 141-144.	3.5	31
178	Characterization of 5â€²AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Lipids and Lipid Metabolism, 1996, 1301, 67-75.	2.6	225
179	Cardiac Efficiency Is Improved After Ischemia by Altering Both the Source and Fate of Protons. Circulation Research, 1996, 79, 940-948.	4.5	176
180	Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Cardiovascular Research, 1995, 30, 432-439.	3.8	64

#	Article	IF	Citations
181	The role of nitric oxide in cardiac depression induced by interleukinâ€1Î² and tumour necrosis factorâ€Î±. British Journal of Pharmacology, 1995, 114, 27-34.	5.4	212
182	Role of NO in vascular smooth muscle and cardiac muscle function. Trends in Pharmacological Sciences, 1994, 15, 255-259.	8.7	90
183	Mechanisms of cytokine-induced destruction of rat insulinoma cells: the role of nitric oxide. Endocrinology, 1994, 134, 1006-1010.	2.8	17
184	Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1058-1062.	3.6	77
185	Analysis of Myocardial Plasmalogen and Diacyl Phospholipids and Their Arachidonic Acid Content Using High-Performance Liquid Chromatography. Analytical Biochemistry, 1993, 213, 140-146.	2.4	9
186	Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase. British Journal of Pharmacology, 1993, 108, 1107-1110.	5.4	53
187	Production of 15-HETE by Cultured Smooth Muscle Cells from Cerebral Artery. Pharmacology, 1993, 46, 211-223.	2.2	10
188	Lysoplasmenylethanolamine accumulation in ischemic/reperfused isolated fatty acid-perfused hearts.. Circulation Research, 1992, 70, 1161-1168.	4.5	25
189	Induction and potential biological relevance of a Ca²⁺â€independent nitric oxide synthase in the myocardium. British Journal of Pharmacology, 1992, 105, 575-580.	5.4	578
190	Nitric oxide synthase in cultured endocardial cells of the pig. British Journal of Pharmacology, 1991, 104, 21-24.	5.4	142
191	The l-Arginine. Journal of Cardiovascular Pharmacology, 1991, 17, S1-S9.	1.9	72
192	Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2166-2170.	7.1	472
193	Cerebral arteries can generate 5- and 15-hydroxyeicosatetraenoic acid from arachidonic acid. Canadian Journal of Physiology and Pharmacology, 1990, 68, 807-813.	1.4	17
194	Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. British Journal of Pharmacology, 1990, 101, 746-752.	5.4	1,734
195	Effects of Vasospasm on Levels of Prostacyclin and Thromboxane A2 in Cerebral Arteries of the Monkey. Neurosurgery, 1988, 22, 45-50.	1.1	44
196	Mechanisms of arachidonic acid-induced contractions of canine cerebral arteries. European Journal of Pharmacology, 1987, 136, 345-352.	3.5	21
197	Release of leukotrienes into the perfusate of calcium-ionophore stimulated rabbit lungs. Biochemical Pharmacology, 1986, 35, 183-193.	4.4	54
198	An efficient and highly flexible synthesis of (Î±),Î²-unsaturated Î³-oxoesters. Tetrahedron Letters, 1982, 23, 2013-2016.	1.4	13